Treatment Strategy and Standard of Care

Treating CIDP is not a “one size fits all” process. The goal of treatment is to stop the immune system’s attack on your nerves, improve your physical function, and prevent long-term damage ^[1][2]. According to the 2021 EAN/PNS guidelines, doctors follow a structured path to find the right “key” for your specific condition ^[1].

First-Line: The Starting Point

Most patients begin with one of three primary treatments. All three are considered “gold standard” options with strong evidence for their effectiveness, but each comes with its own risk profile ^[1]:

• Intravenous Immunoglobulin (IVIG): This is a filtered blood product containing healthy antibodies from thousands of donors. It works by “neutralizing” the harmful antibodies in your system and calming the immune attack ^[1]. Side Effects & Risks: Common side effects include headaches, fatigue, and flu-like symptoms. In rare cases, there is a risk of blood clots or aseptic meningitis, so hydration before infusions is key.
• Corticosteroids: Medications like prednisone or dexamethasone work by broadly suppressing the immune system to reduce inflammation ^[1]. Side Effects & Risks: While effective, they come with significant long-term risks such as weight gain, mood changes, osteoporosis, and diabetes, which require careful monitoring.
• Plasma Exchange (PLEX): Guidelines consider PLEX to be equally as effective as IVIG or steroids for first-line treatment, but it is often used as a backup because it is an invasive procedure requiring specialized equipment ^[1]. Your blood is filtered through a machine to physically remove harmful antibodies. Side Effects & Risks: Side effects include fatigue, blood pressure drops, and risks related to the catheter or blood volume changes.

Maintenance: Preventing the “Wear-Off”

Once your symptoms are under control, the focus shifts to maintenance therapy—keeping you stable with the lowest possible dose.

Many patients on IVIG notice a “wear-off” effect, where their symptoms begin to return a few days before their next scheduled infusion ^[3][4]. To solve this, doctors may switch patients to Subcutaneous Immunoglobulin (SCIG).

• How it works: SCIG is infused under the skin, usually once or twice a week, rather than into a vein every few weeks ^[5].
• The Benefit: Because it is given more frequently, it keeps the level of medicine in your blood much steadier, eliminating the “peaks and valleys” of IVIG. Additionally, one of the major lifestyle benefits of SCIG is that it can often be administered by the patient themselves at home, restoring a sense of independence ^[3][6].

New Horizons: Efgartigimod

A new class of medicine called FcRn antagonists (specifically efgartigimod) has recently shown significant promise for CIDP ^[7]. Instead of adding “good” antibodies (like IVIG), efgartigimod works like a “vacuum cleaner” that specifically targets and removes IgG antibodies from your system ^[8]. In a major clinical trial (ADHERE), it significantly reduced the risk of relapse compared to a placebo, offering a new option for those who may not want or cannot tolerate standard therapies ^[7].

The Refractory Path: When First-Line Fails

Approximately 20% of patients are “refractory,” meaning they do not respond sufficiently to standard first-line treatments ^[9]. If you fall into this group, your doctor’s decision tree may include:

1. Re-evaluating the Diagnosis: Double-checking for “mimics” or the Autoimmune Nodopathies discussed on previous pages ^[10].
2. Combination Therapy: Using both IVIG and steroids together ^[1].
3. Immunosuppressants: Adding medications like rituximab (especially if nodal antibodies are present) or other drugs that suppress the immune system over the long term ^[11][12]. Remember to update your vaccines before starting these, as they severely limit your immune system’s response to infection.

The journey to the right treatment can take time, but with modern options, the vast majority of patients can find a strategy that stabilizes their disease and protects their mobility ^[1].